See the DrugPatentWatch profile for tigecycline

Yes, Tigecycline can be used to treat severe drug-resistant bacterial infections. It is an antibiotic that is often used when other antibiotics have failed to treat an infection. Tigecycline is a broad-spectrum antibiotic, meaning it is effective against a wide range of bacteria [1].

Tigecycline is a glycylcycline antibiotic, a class of antibiotics that is derived from tetracyclines. It works by inhibiting the bacterial protein synthesis [2]. This makes it an effective treatment option for drug-resistant bacteria that have developed resistance to other antibiotics.

Tigecycline is indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [3]. It is important to note that Tigecycline is not recommended as a first-line treatment and should be used only when other antibiotics are not suitable [4].

According to DrugPatentWatch.com, Tigecycline is currently off-patent in the United States, which means that generic versions of the drug are available [5]. This can make Tigecycline a more affordable option for treating drug-resistant bacterial infections.

In summary, Tigecycline can be used to cure severe drug-resistant bacterial infections, particularly those that are unresponsive to other antibiotics. It is a broad-spectrum antibiotic that works by inhibiting bacterial protein synthesis. Tigecycline is indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia.

Sources:

1. Tigecycline. (2021). Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK519535/>
2. Tigecycline: a review of its use in the treatment of intra-abdominal infections. (2010). Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936582/>
3. Tigecycline (Injection). (2018). Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s032lbl.pdf>
4. Tigecycline. (2019). Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK538223/>
5. Tigecycline. (2022). Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>